Marcela Valderama Maus MD PhD

PubMed

• Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.
  Matthew J Frigault, Ning Yao, Trisha R Berger, Marc Wehrli, Kathleen M E Gallagher
  Blood Advances. 2025-05-13
• T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy.
  Kai Rejeski, Jaime Sanz, Teng Fei, Monica S Nair, Hamza Hashmi
  Blood. 2025-04-21
• Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma.
  Joshua N Gustine, Andrew R Branagan, Diana D Cirstea, Farah Rexha, Ryan Han
  Blood Advances. 2025-04-09

Journal Articles

• Making CAR T Cells a Solid Option for Solid Tumors  
  Marcela Maus, MD, Frontiers in Neurology
• Immunotherapy for Glioblastoma: Adoptive T-cell Strategies  
  Marcela V Maus, Carl H June, Clinical Cancer Research

Abstracts/Posters

• Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors
  Marcela V Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)
  Marcela V. Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all